JP2000511407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000511407A5 JP2000511407A5 JP1997538216A JP53821697A JP2000511407A5 JP 2000511407 A5 JP2000511407 A5 JP 2000511407A5 JP 1997538216 A JP1997538216 A JP 1997538216A JP 53821697 A JP53821697 A JP 53821697A JP 2000511407 A5 JP2000511407 A5 JP 2000511407A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611796P | 1996-04-24 | 1996-04-24 | |
| US60/016,117 | 1996-04-24 | ||
| US1778596P | 1996-05-15 | 1996-05-15 | |
| US60/017,785 | 1996-05-15 | ||
| PCT/US1997/006563 WO1997040145A1 (en) | 1996-04-24 | 1997-04-24 | Inactivation resistant factor viii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007101700A Division JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000511407A JP2000511407A (ja) | 2000-09-05 |
| JP2000511407A5 true JP2000511407A5 (OSRAM) | 2004-12-02 |
| JP3987114B2 JP3987114B2 (ja) | 2007-10-03 |
Family
ID=26688196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53821697A Expired - Fee Related JP3987114B2 (ja) | 1996-04-24 | 1997-04-24 | 不活性化耐性第▲８▼因子 |
| JP2007101700A Expired - Fee Related JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007101700A Expired - Fee Related JP4250661B2 (ja) | 1996-04-24 | 2007-04-09 | 不活性化耐性第ｖｉｉｉ因子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6838437B2 (OSRAM) |
| EP (3) | EP2202242A1 (OSRAM) |
| JP (2) | JP3987114B2 (OSRAM) |
| AT (2) | ATE502958T1 (OSRAM) |
| AU (1) | AU3202797A (OSRAM) |
| CA (1) | CA2252896C (OSRAM) |
| DE (2) | DE69735421T2 (OSRAM) |
| DK (1) | DK1754718T3 (OSRAM) |
| PT (1) | PT1754718E (OSRAM) |
| WO (1) | WO1997040145A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2221567A1 (en) * | 1995-06-12 | 1996-12-27 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Ned Erlandse Rode Kruis | Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation |
| US20040092442A1 (en) * | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
| ATE502958T1 (de) | 1996-04-24 | 2011-04-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
| AU3289599A (en) * | 1998-02-13 | 1999-08-30 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
| EP1351986A2 (en) * | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| WO2003100053A1 (en) * | 2002-05-22 | 2003-12-04 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hemophilia a |
| US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| EP1831242B1 (en) | 2004-12-23 | 2012-09-26 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest |
| WO2006108590A1 (en) * | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| CA2656558A1 (en) * | 2006-06-30 | 2008-01-10 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
| RU2528855C2 (ru) | 2008-06-24 | 2014-09-20 | Цсл Беринг Гмбх | Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения |
| CA2816575C (en) * | 2010-11-05 | 2019-06-11 | Baxter Healthcare S.A. | A new variant of antihemophilic factor viii having increased specific activity |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| US9394353B2 (en) | 2011-10-18 | 2016-07-19 | Csl Limited | Method for improving the stability of purified factor VIII after reconstitution |
| ES2600081T3 (es) | 2011-10-18 | 2017-02-07 | Csl Behring Gmbh | Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII |
| DK2768521T3 (en) | 2011-10-18 | 2016-10-24 | Csl Behring Gmbh | Combined use of a sulfated glykosamin glycan and a Hyaluronidase to improve bio-availability of factor VIII |
| EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
| WO2014041500A2 (en) * | 2012-09-12 | 2014-03-20 | Centre For Bioseparation Technology-Vit | Double mutant coagulation factor viii and methods thereof |
| CN104812402A (zh) * | 2012-11-29 | 2015-07-29 | 拜尔健康护理有限责任公司 | 针对活化蛋白C (aPC)的单克隆抗体 |
| HK1215174A1 (zh) | 2012-11-29 | 2016-08-19 | Bayer Healthcare Llc | 針對活化蛋白c的人源化單克隆抗體及其用途 |
| ES2680942T3 (es) * | 2013-03-15 | 2018-09-11 | Bayer Healthcare Llc | Variante de polipéptidos del factor VIII y procedimientos para su producción y utilización |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| US10253088B2 (en) | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
| JP6704420B2 (ja) * | 2015-03-06 | 2020-06-03 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | フォンヴィレブランド因子の半減期を改善するための化合物 |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| EP3297656B1 (en) | 2015-05-22 | 2020-01-08 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| KR20180012303A (ko) | 2015-05-22 | 2018-02-05 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 변형된 폰 빌레브란트 인자의 제조 방법 |
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| CA3010720A1 (en) | 2016-01-07 | 2017-07-13 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| SG10201912360SA (en) | 2016-11-11 | 2020-02-27 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| US11890327B2 (en) | 2016-11-11 | 2024-02-06 | CSL Behring Lengnau AG | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| WO2020086686A2 (en) * | 2018-10-23 | 2020-04-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US20220403005A1 (en) * | 2019-12-06 | 2022-12-22 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214033A (en) * | 1983-03-31 | 1993-05-25 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5045455A (en) * | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| SE8501050D0 (sv) | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| WO1986006101A1 (en) | 1985-04-12 | 1986-10-23 | Genetics Institute, Inc. | Novel procoagulant proteins |
| WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| AT388079B (de) | 1986-04-18 | 1989-04-25 | Helmut Ing Koenig | Backofen |
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| JP2865861B2 (ja) | 1989-11-17 | 1999-03-08 | ノボ ノルディスク アクティーゼルスカブ | 第▲ｖｉｉｉ▼：ｃ因子活性を有するタンパク質複合体およびその製法 |
| US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5563045A (en) * | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| AU6486196A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| WO1997003194A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Lysine 1689 factor viii:c polypeptide analogs |
| ATE502958T1 (de) | 1996-04-24 | 2011-04-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
-
1997
- 1997-04-24 AT AT06004484T patent/ATE502958T1/de active
- 1997-04-24 WO PCT/US1997/006563 patent/WO1997040145A1/en not_active Ceased
- 1997-04-24 EP EP10157809A patent/EP2202242A1/en not_active Withdrawn
- 1997-04-24 JP JP53821697A patent/JP3987114B2/ja not_active Expired - Fee Related
- 1997-04-24 EP EP97927596A patent/EP0910628B1/en not_active Expired - Lifetime
- 1997-04-24 DE DE69735421T patent/DE69735421T2/de not_active Expired - Lifetime
- 1997-04-24 AU AU32027/97A patent/AU3202797A/en not_active Abandoned
- 1997-04-24 AT AT97927596T patent/ATE319817T1/de not_active IP Right Cessation
- 1997-04-24 CA CA002252896A patent/CA2252896C/en not_active Expired - Fee Related
- 1997-04-24 PT PT06004484T patent/PT1754718E/pt unknown
- 1997-04-24 DE DE69740154T patent/DE69740154D1/de not_active Expired - Lifetime
- 1997-04-24 EP EP06004484A patent/EP1754718B1/en not_active Expired - Lifetime
- 1997-04-24 DK DK06004484.9T patent/DK1754718T3/da active
-
2001
- 2001-04-11 US US09/819,098 patent/US6838437B2/en not_active Expired - Fee Related
-
2004
- 2004-10-26 US US10/974,534 patent/US7459534B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 JP JP2007101700A patent/JP4250661B2/ja not_active Expired - Fee Related